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Recently proposed criteria for prodromal Alzheimer
disease (AD),1 mild cognitive impairment (MCI) due
to AD,2 and probable AD dementia3 incorporate
molecular evidence of amyloid- (A) pathology
and also consider measures of brain structure and
function as supportive biomarkers. MRI-based bio-
markers are also proposed as supportive evidence for
a diagnosis of preclinical AD4 in cognitively normal
individuals, posing new challenges for definition, val-
idation, and interpretation of these biomarkers. A
number of MRI-based biomarkers, such as volumes
of hippocampus and entorhinal cortex, show robust
differences between groups of patients with AD and
controls. However, these measures have limited sen-
sitivity and specificity in predicting who will develop
AD in individual patients. The development and val-
idation of new structural neuroimaging biomarkers
sensitive to early changes in the disease process will
be critical to implementation of the new research cri-
teria for preclinical AD.
In this issue of Neurology®, Dickerson and Wolk5
investigate the utility of a potential MRI biomarker
of neurodegeneration, based on a previously identi-
fied set of 9 brain regions that show cortical thinning
in AD, MCI, and cognitively normal individuals
with A deposition on PET imaging. Using MRI
data from 159 cognitively normal individuals in
the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), the authors test the hypothesis that individ-
uals at high risk for preclinical AD based on this “AD
signature” of regional cortical thinning would be at
increased risk for subsequent cognitive decline over a
3-year follow-up. Based on the AD signature scores,
cognitively normal individuals were classified as
high, average, or low risk of preclinical AD. Signifi-
cant cognitive decline was operationalized as an in-
crease of 1.0 on the Clinical Dementia Rating
Scale Sum of Boxes score and a decline of1 SD on
one of the following measures: immediate recall on a
measure of verbal learning, verbal delayed free recall,
or executive function measured by Trails B. The au-
thors report that normal individuals at high risk for
preclinical AD are more likely to show cognitive de-
cline, with risks of cognitive decline equal to 21% in
the high-risk, 7% in the average-risk, and 0% in the
low-risk group. This represents a 3-fold increase in
risk for cognitive decline for each 1 SD of cortical
thinning. In addition, 60% of the high-risk group
had CSF characteristics (low CSF A) suggestive of
AD in the subsample for which CSF data were
available.
Dickerson and Wolk provide additional support
for the utility of MRI-based biomarkers in identify-
ing cognitively normal individuals at increased risk
for cognitive impairment and AD. Importantly, the
regions contributing to the cortical thinning “AD
signature” were defined in previous work by the au-
thors and were applied in the current investigation to
a new sample, the ADNI controls who had prospec-
tive cognitive follow-ups. The use of multiple brain
regions to develop a composite measure of brain ab-
normality is an additional strength of this work. The
authors show that their composite AD signature,
compared with entorhinal cortex thickness, provides
better discrimination between individuals who show
cognitive decline vs stable performance at follow-up.
Composite measures of networks of brain regions
that discriminate between normal and pathologic
brains are likely to yield more informative prediction
on an individual patient basis as compared to single
regions alone, as shown in prior studies using support
vector machine learning methods to distinguish spa-
tial patterns of abnormality that identify the earliest
stages of AD.6
Although the sample size in the current study was
small (only 14 individuals with complete cognitive
follow-up data met the criteria for high risk for pre-
clinical AD) and longer follow-up intervals will be
required to validate the AD signature against other
(imaging) biomarkers, the ability to identify cogni-
tively normal individuals at higher risk for subse-
quent cognitive decline is an important step toward
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implementing and evaluating the new criteria for
preclinical AD. Combinations of A biomarkers and
structural imaging biomarkers of subtle regional neu-
rodegeneration, along with their time course, may
also help distinguish cognitively normal individuals
with A pathology who will develop disease from
those who will remain asymptomatic during their
lifetime. Data from autopsy and PET amyloid imag-
ing studies show that about 30% of individuals with
normal cognitive function have substantial amyloid
pathology. Although some argue that this group rep-
resents preclinical AD,2 the absence of antemortem
cognitive decline in prospective autopsy samples of
“asymptomatic AD” suggests that a subgroup of in-
dividuals may demonstrate cognitive resilience de-
spite substantial pathology.7 In this group in
particular, the presence of the “AD signature” in the
structural, downstream, imaging marker may be pre-
dictive of who will actually decline. Distinguishing
individuals who will decline from those who will re-
main asymptomatic is essential for patient selection
and monitoring in therapeutic trials and for identifi-
cation of individuals most likely to benefit from po-
tential treatments to delay the onset of cognitive
impairment.
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